Humira (adalimumab) lost exclusivity in 2023, and a wave of FDA-approved biosimilars followed. They're the same class of drug at a lower cost, so payers have strong incentive to prefer them. In practice some plans dropped brand Humira entirely. For example, in our data UnitedHealthcare's marketplace plans list zero brand Humira but carry several adalimumab biosimilars — so a member searching "Humira" would see it as not covered, while the biosimilar is.
Check Humira on your specific plan — and if it's not covered, we show the covered adalimumab biosimilars instantly.
Look up a drug — freeGenerally yes — adalimumab is on most Medicare Part D plans, but on a high specialty tier with prior authorization, and many plans now prefer a biosimilar. Use the lookup to check your plan.
FDA-approved adalimumab biosimilars include Amjevita, Cyltezo, Hyrimoz, Hadlima, Yuflyma, Hulio, Idacio, Abrilada, Yusimry and others. Which one your plan prefers varies by plan.
That usually means the plan covers a biosimilar instead. Our lookup shows the covered same-ingredient options on your plan; bring that list to your prescriber to discuss switching.
The FDA approves biosimilars only when they have no clinically meaningful differences from the reference product. Still, any switch is a decision to make with your clinician.